Abstract
Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Current Pharmaceutical Biotechnology
Title: The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems
Volume: 6 Issue: 1
Author(s): O. Kayser, A. Lemke and N. Hernandez-Trejo
Affiliation:
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Abstract: Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Export Options
About this article
Cite this article as:
Kayser O., Lemke A. and Hernandez-Trejo N., The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167158
DOI https://dx.doi.org/10.2174/1389201053167158 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Self-Assembly of DNA and Cell-Adhesive Proteins onto pH-Sensitive Inorganic Crystals for Precise and Efficient Transgene Delivery
Current Pharmaceutical Design The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism Hyperpolarized 13Carbon MR
Current Pharmaceutical Biotechnology Editorial [Personalized Vaccines and Public Health Genomics: Anticipating and Monitoring the ELSIs]
Current Pharmacogenomics and Personalized Medicine Inhibition of NF-kB Activation and Cytokines Production in THP-1 Monocytes by 2-Styrylchromones
Medicinal Chemistry Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8
Anti-Cancer Agents in Medicinal Chemistry Hormone Replacement Therapy in Rheumatoid Arthritis
Current Rheumatology Reviews Bio-AIMS Collection of Chemoinformatics Web Tools based on Molecular Graph Information and Artificial Intelligence Models
Combinatorial Chemistry & High Throughput Screening Effect of Short-term Quercetin, Caloric Restriction and Combined Treatment on Age-related Oxidative Stress Markers in the Rat Cerebral Cortex
CNS & Neurological Disorders - Drug Targets Design and Cytotoxicity Analysis of a Conjugate Containing the New DGalactose- Binding Lectin SELld and the Non-Toxic Type 2 Ribosome- Inactivating Protein Nigrin b
Letters in Drug Design & Discovery Recent Advance of Computational Approaches in Genomics and Proteomics
Current Bioinformatics Flow-Injection Potentiometric Method for the Routine Determination of Chloride: Application to Bread Analysis
Current Analytical Chemistry Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Chemotherapy of Non-small Cell Lung Cancer in Elderly Patients
Current Medicinal Chemistry Interleukin-10: An Anti-Inflammatory and Immunosuppressive Cytokine in the Normal and Pathological Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in the Chemistry and Synthesis of Thienopyrazine, Pyrrolopyrazine and Furopyrazine Derivatives
Current Organic Chemistry Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry